1989
DOI: 10.1002/jmv.1890290212
|View full text |Cite
|
Sign up to set email alerts
|

Complement‐Independent neutralising monoclonal antibody with differential reactivity for strains of human cytomegalovirus

Abstract: A mouse monoclonal antibody with complement-independent neutralising activity against cytomegalovirus (CMV) and reactive with the 86 kilodalton (kDa) viral glycoprotein H is described. Neutralisation tests against a range of different strains of CMV showed significant crossreactivity, but clear differences were evident between the two prototype viruses AD169 and Davis, and particularly between AD169 and several low-passage recent clinical isolates; CMV present in urine was neutralised weakly if at all.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
17
0

Year Published

1993
1993
2009
2009

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(19 citation statements)
references
References 24 publications
(7 reference statements)
2
17
0
Order By: Relevance
“…One likely possibility, based on the precedence in other viruses such as influenza viruses, may be related to evasion of virus-neutralizing antibodies secondary to sequence variation in envelope glycoproteins. Consistent with this possibility has been the finding of antigenic diversity among HCMV isolates that precludes complete neutralization by a given polyclonal serum or monoclonal antibody, a finding that is wellestablished and documented in numerous studies (Waner & Weller, 1978;Baboonian et al, 1989;Simpson et al, 1993;Klein et al, 1999). Of special interest in this respect are virus envelope glycoproteins, as they represent the targets for neutralizing antibodies.…”
Section: Introductionmentioning
confidence: 48%
“…One likely possibility, based on the precedence in other viruses such as influenza viruses, may be related to evasion of virus-neutralizing antibodies secondary to sequence variation in envelope glycoproteins. Consistent with this possibility has been the finding of antigenic diversity among HCMV isolates that precludes complete neutralization by a given polyclonal serum or monoclonal antibody, a finding that is wellestablished and documented in numerous studies (Waner & Weller, 1978;Baboonian et al, 1989;Simpson et al, 1993;Klein et al, 1999). Of special interest in this respect are virus envelope glycoproteins, as they represent the targets for neutralizing antibodies.…”
Section: Introductionmentioning
confidence: 48%
“…This is in contrast to the second immunodominant envelope protein, gB, where seropositivity rates for native or denatured protein were identical. The high percentage of conformation-dependent antibodies against gH could also provide an explanation for the findings that gH specific MAbs, if not developed against prokaryotic fusion proteins, recognize conformational epitopes (Baboonian et al, 1989;Cranage et al, 1988;Rasmussen et al, I984;Simpson et al, 1993).…”
Section: Discussionmentioning
confidence: 99%
“…Fixation of insect cells using acetone could potentially alter antigenic structures necessary for binding of certain types of antibodies. In addition, gH specific MAbs show a wide range of neutralizing activity when different HCMV strains are compared (Baboonian et al, 1989;Rasmussen et al, 1984;Simpson et al, 1993). This could indicate that despite the high homology found between gH proteins from various isolates (Chou, 1992), strain specific recognition and neutralization takes place, mediated through minor differences between different gH molecules.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The complement-independent neutralizing gH-specific MAb were : C2 (Baboonian et al, 1989) and HCMV-16 (Cogent Diagnostics ;Cranage et al, 1988). The non-neutralizing MAb were : C13 (specific for ppUL83 ; Baboonian et al, 1989) and HCMV-34 (specific for gB ; Cogent Diagnostics), all in the form of mouse ascitic fluids. Pre-and post-immunization guinea-pig sera with complementindependent neutralizing activity, specific for HCMV gB, were the generous gift of Dirk Gheysen (SmithKline Beecham).…”
Section: Methodsmentioning
confidence: 99%